@inproceedings{inproceedings, title = {{A phase IIa study of amlitelimab, a novel nondepleting anti-OX40Ligand mAb in patients with moderate to severe atopic dermatitis}}, url = {{}}, year = {{2022}}, month = {{1}}, author = {{Weidinger S and Cork M and Reich A and Beiber T and Gilbert S and Brennan N and Wilson R and Quaratino S and Porter-Brown B}}, volume = {{187}}, journal = {{BRITISH JOURNAL OF DERMATOLOGY}}, issue = {{3}}, pages = {{E96-E96}}, note = {{Accessed on 2025/10/08}}}